FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (I),
in which V is selected from C and N so that the aromatic ring containing V is phenyl or pyridine; R2 is absent when V is N; or, when present, R2 is selected from H, alkyl, alkoxy and halogen; R1 and R3 are independently selected from H, alkyl, alkoxy, halogen and CF3; W, X, Y and Z are independently selected from C and N, so that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle; where R5, R6 and R7 are independently absent or independently selected from H, alkyl, aryl and CF3; P represents -C(R10)(R11)NH2; A is selected from aryl and heteroaryl; alkyl is a linear saturated hydrocarbon containing up to 6 carbon atoms (C1-C6), or a branched saturated hydrocarbon containing from 3 to 6 carbon atoms (C3-C6); alkyl, optionally, may be substituted with -NR12R13; cycloalkyl is a monocyclic saturated hydrocarbon containing from 3 to 7 carbon atoms; alkoxy is a linear O-linked hydrocarbon containing from 1 to 6 carbon atoms (C1-C6), or a branched O-linked hydrocarbon containing from 3 to 6 carbon atoms (C3-C6); alkoxy, optionally, may be substituted with aryl; aryl is phenyl; aryl, optionally, may be substituted with a substituent selected from alkyl, alkoxy, halogen, CN, -morpholinyl, -piperidinyl, heteroaryl, arylb, -O-arylb, -CH2- arylb, -(CH2)1-3-heteroaryl, -CONR12R13, -(CH2)1-3-NR14R15 and NR12R13; heteroaryl is a 5, 6, 9 or 10-membered mono- or bicyclic aromatic ring containing, where possible, 1 or 2 ring members, independently selected from N, S and O; heteroaryl, optionally, may be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, morpholinyl, aryl, -(CH2)1-3-aryl, heteroarylb and NR12R13; values of other radicals are given in the patent claim. Invention also relates to a pharmaceutical composition, to the use of a compound, to a method for treating a disease or condition in which plasma kallikrein activity is involved.
EFFECT: technical result: obtaining novel compounds capable of inhibiting plasma kallikrein.
29 cl, 18 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES USEFUL AS PLASMA KALLIKREIN INHIBITOR | 2014 |
|
RU2712621C2 |
| PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | 2006 |
|
RU2420519C2 |
| HETEROARYL COMPOUNDS AS TKB INHIBITORS AND USE THEREOF | 2015 |
|
RU2742122C2 |
| HETEROCYCLIC COMPOUNDS, THEIR USING AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF STATES MEDIATED BY CXCR4 AND CCR5 | 2001 |
|
RU2277092C2 |
| BICYCLIC INHIBITORS | 2014 |
|
RU2672582C2 |
| ENZYME INHIBITORS | 2014 |
|
RU2674028C2 |
| NOVEL PYRROLE COMPOUNDS, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2607788C2 |
| BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | 2012 |
|
RU2607045C2 |
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2707870C2 |
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2821520C2 |
